140
Participants
Start Date
December 31, 2006
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Gemcitabine
Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
Gemcitabine
Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
Erlotinib
Erlotinib 100 mg by mouth (p.o.), daily until disease progression
Oxaliplatin
Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupoli
Air Forces Military Hospital of Athens, Athens
Errikos Ntynan General Hospital, Athens
IASO General Hospital of Athens, 1st Department of Medical Oncology, Athens
Laikon General Hospital, Medical Oncology Unit, Propedeutic Department of Internal Medicine, Athens
Metaxa's Anticancer Hospital of Piraeus, 1st Department of Medical Oncology, Athens
State General Hospital of Larissa, Larissa
Diabalkaniko General Hospital of Thessaloniki, Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER